|
|
 |
|
Total Number of Holdings (excluding cash): 49
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
541,189 |
$82,065,899.96 |
7.61% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
288,769 |
$75,576,622.68 |
7.01% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
269,821 |
$74,257,437.41 |
6.88% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
63,500 |
$73,665,080.00 |
6.83% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
1,074,681 |
$72,712,916.46 |
6.74% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
174,598 |
$38,877,736.66 |
3.60% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,244,601 |
$38,360,231.09 |
3.56% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
86,517 |
$38,313,188.28 |
3.55% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
67,576 |
$37,622,938.00 |
3.49% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
43,000 |
$36,637,290.00 |
3.40% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Drug Retailers |
146,418 |
$35,944,154.82 |
3.33% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
1,211,906 |
$35,169,512.12 |
3.26% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
224,780 |
$33,629,335.80 |
3.12% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
207,373 |
$26,715,863.59 |
2.48% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
101,385 |
$24,897,114.45 |
2.31% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
49,651 |
$24,429,285.02 |
2.26% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
111,095 |
$23,691,008.75 |
2.20% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
255,495 |
$19,461,054.15 |
1.80% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
64,512 |
$18,822,021.12 |
1.74% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
311,809 |
$18,250,180.77 |
1.69% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
152,050 |
$16,673,803.00 |
1.55% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
26,119 |
$15,489,089.38 |
1.44% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
86,017 |
$12,972,223.77 |
1.20% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
191,498 |
$12,824,621.06 |
1.19% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
98,300 |
$12,877,300.00 |
1.19% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
79,867 |
$12,602,213.93 |
1.17% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
200,179 |
$12,341,035.35 |
1.14% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
253,966 |
$12,119,257.52 |
1.12% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
165,372 |
$11,872,055.88 |
1.10% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
154,629 |
$10,395,707.67 |
0.96% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
107,017 |
$9,315,829.85 |
0.86% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
153,093 |
$8,710,991.70 |
0.81% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
331,272 |
$8,175,792.96 |
0.76% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
49,148 |
$8,014,072.88 |
0.74% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
50,169 |
$7,328,687.52 |
0.68% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
393,736 |
$7,110,872.16 |
0.66% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
226,302 |
$6,755,114.70 |
0.63% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
79,351 |
$6,774,194.87 |
0.63% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
23,051 |
$6,613,792.92 |
0.61% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
16,886 |
$6,234,817.78 |
0.58% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
50,675 |
$6,011,575.25 |
0.56% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
187,890 |
$5,435,657.70 |
0.50% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
159,234 |
$5,442,618.12 |
0.50% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
60,934 |
$5,042,897.84 |
0.47% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
50,163 |
$5,007,772.29 |
0.46% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
171,001 |
$4,078,373.85 |
0.38% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
13,825 |
$3,696,805.00 |
0.34% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
83,982 |
$3,697,727.46 |
0.34% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
56,830 |
$3,485,383.90 |
0.32% |
| US Dollar |
$USD |
|
Other |
2,531,961 |
$2,531,961.37 |
0.23% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|